Technical Study: Amgen Inc., Questcor Pharmaceuticals Inc., PDL BioPharma
Inc., and BioCryst Pharma Inc.
Editor Note: For more information about this release, please scroll to bottom
LONDON, October 17, 2013
LONDON, October 17, 2013 /PRNewswire/ --
The U.S. equity market edged higher on Wednesday, October 16 2013. The S&P 500
ended the day at 1,721.54, up 1.38%; the Dow Jones Industrial Average closed
at 15,373.83, up 1.36%; and the NASDAQ Composite finished at 3,839.43, up
1.20%. Shares in the biotechnology industry edged higher, tracking gains in
the broader market. The major movers in the industry included Amgen Inc.
(NASDAQ: AMGN), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), PDL BioPharma
Inc. (NASDAQ: PDLI), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX).
AAAResearchReports.com free coverage on AMGN, QCOR, PDLI, and BCRX is
available upon registration at:
On Wednesday, Amgen Inc.'s stock close at $114.28, up 2.55% from the previous
day's closing price of $111.44. The company's shares vacillated between
$112.35 and $114.85 during the trading session. A total of 3.49 million shares
were traded, which is above the daily average volume of 3.17 million. The
company's stock has gained 3.06% in the previous three trading sessions and
9.83% in the last three months, outperforming the S&P 500 which has advanced
1.08% and 2.70% during the respective periods. Further, Amgen Inc.'s stock is
trading near its 52-week high of $117.91 and above its 50-day and 200-day
moving averages of $110.87 and $101.08, respectively. Download free technical
research on AMGN by signing up at:
Shares in Questcor Pharmaceuticals Inc. rallied on Wednesday, extending the
gains from the previous trading session. The company's shares ended the day
5.50% higher at $66.73, after trading between $63.30 and $66.95. A total of
1.95 million shares were traded, which is above the daily average volume of
1.80 million. Questcor Pharmaceuticals Inc.'s shares have surged 10.85% in the
previous three trading sessions and 37.19% in the last three months,
outperforming the S&P 500 which has advanced 1.08% and 2.70% during the
respective periods. Moreover, the company's stock is trading above its 50-day
and 200-day moving averages of $63.58 and $42.44, respectively. Register now
and get access to free analysis on QCOR at:
PDL BioPharma Inc.'s stock ended higher on Wednesday, reversing all the losses
from the previous trading session. The company's shares closed the day at
$8.03, up 1.39% from the previous day's price of $7.92. The company's shares
fluctuated between $7.95 and $8.20 during the trading session. A total of 1.43
million shares were traded, which is below the daily average volume of 1.70
million. The company's stock has gained 1.90% in the last one month and 1.01%
in the previous three months, compared to a gain of 1.41% and 2.70% in the S&P
500 during the respective periods. Furthermore, PDL BioPharma Inc.'s stock is
trading above its 50-day and 200-day moving averages of $7.98 and $7.66,
respectively. Sign up and read our complimentary report on PDLI at:
BioCryst Pharmaceuticals Inc.'s stock advanced on Wednesday, tracking gains in
the broader market. The company's shares closed the day 1.22% higher at $6.64,
after oscillating between $6.41 and $6.88. A total of 0.94 million shares were
traded, which is significantly below the daily average volume of 2.52 million.
The company's stock has gained 1.84% in the last one month and 245.83% in the
previous three months, outperforming the S&P 500 which has advanced 1.41% and
2.70% during the respective periods. Additionally, BioCryst Pharmaceuticals
Inc.'s stock is trading above its 50-day and 200-day moving averages of $6.48
and $3.00, respectively. The free report on BCRX can be downloaded by signing
up now at:
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However,
we are only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our subscriber
base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us at
5. For any urgent concerns or inquiries, please contact us at
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID:
Press spacebar to pause and continue. Press esc to stop.